|
English
|
正體中文
|
简体中文
|
总笔数 :2856699
|
|
造访人次 :
53573509
在线人数 :
1008
教育部委托研究计画 计画执行:国立台湾大学图书馆
|
|
|
"shaw a t"的相关文件
显示项目 26-31 / 31 (共2页)
<< < 1 2
每页显示[10|25|50]项目
| 臺大學術典藏 |
2020-05-25T07:34:59Z |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
|
Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgeel S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Peltz G; Ross Camidge D. |
| 臺大學術典藏 |
2020 |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Shaw A.T.; Passos V.Q.; Chen Z.; Viraswami-Appanna K.; Spigel D.R.; Scagliotti G.V.; Mok T.; Su W.-C.; Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU; Tsai C.-M.; Cobo M.; McKeage M.; Nishio M.;Felip E.;Orlov S.;Park K.;Chong-Jen Yu;Tsai C.-M.;Cobo M.;Mckeage M.;Su W.-C.;Mok T.;Scagliotti G.V.;Spigel D.R.;Viraswami-Appanna K.;Chen Z.;Passos V.Q.;Shaw A.T. |
| 臺大學術典藏 |
2020 |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Shaw A.T.; Passos V.Q.; Chen Z.; Viraswami-Appanna K.; Spigel D.R.; Scagliotti G.V.; Mok T.; Su W.-C.; Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU; Tsai C.-M.; Cobo M.; McKeage M.; Nishio M.;Felip E.;Orlov S.;Park K.;Chong-Jen Yu;Tsai C.-M.;Cobo M.;Mckeage M.;Su W.-C.;Mok T.;Scagliotti G.V.;Spigel D.R.;Viraswami-Appanna K.;Chen Z.;Passos V.Q.;Shaw A.T. |
| 國立成功大學 |
2020 |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Nishio, M.;Felip, E.;Orlov, S.;Park, K.;Yu, C.-J.;Tsai, C.-M.;Cobo, M.;McKeage, McKeage M.;Su, W.-C.;Mok, T.;Scagliotti, G.V.;Spigel, D.R.;Viraswami-Appanna, K.;Chen, Z.;Passos, V.Q.;Shaw, A.T. |
| 臺大學術典藏 |
2019 |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial
|
Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I. |
| 臺大學術典藏 |
2019 |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial
|
Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I. |
显示项目 26-31 / 31 (共2页)
<< < 1 2
每页显示[10|25|50]项目
|
